High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia

BW Teh; W Chui; S Handunnetti; C Tam; LJ Worth; KA Thursky; MA Slavin

Journal article

High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia

BW Teh, W Chui, S Handunnetti, C Tam, LJ Worth, KA Thursky, MA Slavin

Leukemia and Lymphoma | TAYLOR & FRANCIS LTD | Published : 2019

DOI: 10.1080/10428194.2018.1543884

University of Melbourne Researchers

Benjamin Teh Author

Constantine Tam Author

Leon Worth Author

Kas Thursky Author

Grants

Funding Acknowledgements

Dr. Benjamin W. Teh is supported by a National Health and Medical Research Council Early Career fellowship and Peter MacCallum Cancer Centre clinical research fellowship. This study did not receive external funding. B.W.T has received speaker fees from Gilead. S.H has received an honorarium from Gilead and educational grant from Abbvie. C.S.T has received research funding and honorarium from Janssen and Abbvie and honorarium from Gilead. M.A.S has received research funding and honorarium from Merck Sharpe and Dohme and Gilead.